SPOILER ALERT: This piece contains spoilers for the Season 5 finale episode of Only Murders in the Building.
Another Arconia murder mystery has come and gone, but another dead body was found on the premises, though it could be argued that…
Prince Harry sat down with Hasan Minhaj for an episode of the comedian’s “Hasan Minhaj Doesn’t Know” podcast. It turned out to be one of the Duke of Sussex’s most candid interviews yet.
Keep reading to see what the Duke of Sussex revealed…
MORE:…
The property sector is seeing an influx of local and international capacity.
Australia’s insurance market is entering a softening phase as competition increases, particularly in property and financial lines, according to WTW’s latest Global…
The Vera Rubin Observatory (VRO) hasn’t yet begun it’s much-anticipated Legacy Survey of Space and Time. But it saw its first light in June 2025, when it captured its Virgo First Look images as part of commisioning its main camera. Those…
Barbara Plett UsherAfrica correspondent
BBCShaken, scratched and left with just the clothes he is wearing, Ezzeldin Hassan Musa describes the brutality of Sudan’s Rapid Support…
SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London.
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your Jefferies representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco, California. For further information, visit http://www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
[email protected]
SOURCE Nektar Therapeutics
Prince Andrew will soon simply be known as Andrew Mountbatten Windsor after the process to strip the disgraced brother of King Charles III of all of his royal titles began today, but his daughters will keep theirs.
The formal process to remove…
PARIS – Jannik Sinner eased past Francisco Cerundolo 7-5, 6-1 at the Paris Masters on Oct 30 to set up a quarter-final clash with Ben Shelton, while reigning champion Alexander Zverev earned a straight-sets win over Alejandro Davidovich Fokina in…
Samsung finally launched its Galaxy XR headset this month, so now everyone wants to know: What’s the battery life like?
While Mashable has yet to perform nuanced battery testing of our own, we at…